The  ||| S:0 E:4 ||| DT
contribution  ||| S:4 E:17 ||| NN
of  ||| S:17 E:20 ||| IN
non-human  ||| S:20 E:30 ||| JJ
primate  ||| S:30 E:38 ||| JJ
models  ||| S:38 E:45 ||| NNS
to  ||| S:45 E:48 ||| TO
the  ||| S:48 E:52 ||| DT
development  ||| S:52 E:64 ||| NN
of  ||| S:64 E:67 ||| IN
human  ||| S:67 E:73 ||| JJ
vaccines  ||| S:73 E:82 ||| NNS
The  ||| S:82 E:86 ||| DT
non-human  ||| S:86 E:96 ||| JJ
primates  ||| S:96 E:105 ||| NNS
( ||| S:105 E:106 ||| -LRB-
NHPs ||| S:106 E:110 ||| NNP
)  ||| S:110 E:112 ||| -RRB-
model  ||| S:112 E:118 ||| NN
in  ||| S:118 E:121 ||| IN
biomedical  ||| S:121 E:132 ||| JJ
research  ||| S:132 E:141 ||| NN
has  ||| S:141 E:145 ||| VBZ
contributed  ||| S:145 E:157 ||| VBN
to  ||| S:157 E:160 ||| TO
the  ||| S:160 E:164 ||| DT
study  ||| S:164 E:170 ||| NN
of  ||| S:170 E:173 ||| IN
human  ||| S:173 E:179 ||| JJ
infectious ||| S:179 E:189 ||| NN
,  ||| S:189 E:191 ||| ,
autoimmune ||| S:191 E:201 ||| NN
,  ||| S:201 E:203 ||| ,
oncogenic ||| S:203 E:212 ||| NN
,  ||| S:212 E:214 ||| ,
and  ||| S:214 E:218 ||| CC
neurological  ||| S:218 E:231 ||| JJ
diseases ||| S:231 E:239 ||| NNS
.  ||| S:239 E:241 ||| .
This  ||| S:241 E:246 ||| DT
review  ||| S:246 E:253 ||| NN
focuses  ||| S:253 E:261 ||| VBZ
on  ||| S:261 E:264 ||| IN
the  ||| S:264 E:268 ||| DT
importance  ||| S:268 E:279 ||| NN
of  ||| S:279 E:282 ||| IN
NHP  ||| S:282 E:286 ||| NNP
models  ||| S:286 E:293 ||| NNS
in  ||| S:293 E:296 ||| IN
vaccine  ||| S:296 E:304 ||| NN
development  ||| S:304 E:316 ||| NN
for  ||| S:316 E:320 ||| IN
tuberculosis ||| S:320 E:332 ||| NN
,  ||| S:332 E:334 ||| ,
pertussis ||| S:334 E:343 ||| NN
,  ||| S:343 E:345 ||| ,
Dengue ||| S:345 E:351 ||| NNP
,  ||| S:351 E:353 ||| ,
group  ||| S:353 E:359 ||| NN
A  ||| S:359 E:361 ||| DT
streptococcus  ||| S:361 E:375 ||| NN
( ||| S:375 E:376 ||| -LRB-
Streptococcus  ||| S:376 E:390 ||| UH
pyogenes ||| S:390 E:398 ||| UH
)  ||| S:398 E:400 ||| -RRB-
infection ||| S:400 E:409 ||| NN
,  ||| S:409 E:411 ||| ,
HIV  ||| S:411 E:415 ||| NNP
infection ||| S:415 E:424 ||| NN
,  ||| S:424 E:426 ||| ,
and  ||| S:426 E:430 ||| CC
certain  ||| S:430 E:438 ||| JJ
diseases  ||| S:438 E:447 ||| NNS
in  ||| S:447 E:450 ||| IN
the  ||| S:450 E:454 ||| DT
elderly  ||| S:454 E:462 ||| JJ
( ||| S:462 E:463 ||| -LRB-
influenza ||| S:463 E:472 ||| UH
,  ||| S:472 E:474 ||| ,
for  ||| S:474 E:478 ||| IN
example ||| S:478 E:485 ||| NN
) ||| S:485 E:486 ||| -RRB-
.  ||| S:486 E:488 ||| .
From  ||| S:488 E:493 ||| IN
understanding  ||| S:493 E:507 ||| VBG
disease  ||| S:507 E:515 ||| NN
pathogenesis  ||| S:515 E:528 ||| NNS
and  ||| S:528 E:532 ||| CC
mechanisms  ||| S:532 E:543 ||| NNS
of  ||| S:543 E:546 ||| IN
protection ||| S:546 E:556 ||| NN
,  ||| S:556 E:558 ||| ,
to  ||| S:558 E:561 ||| TO
assessing  ||| S:561 E:571 ||| VBG
vaccine  ||| S:571 E:579 ||| NN
safety  ||| S:579 E:586 ||| NN
and  ||| S:586 E:590 ||| CC
efficacy ||| S:590 E:598 ||| NN
,  ||| S:598 E:600 ||| ,
we  ||| S:600 E:603 ||| PRP
discuss  ||| S:603 E:611 ||| VB
selected  ||| S:611 E:620 ||| VBN
cases  ||| S:620 E:626 ||| NNS
where  ||| S:626 E:632 ||| WRB
the  ||| S:632 E:636 ||| DT
importance  ||| S:636 E:647 ||| NN
of  ||| S:647 E:650 ||| IN
the  ||| S:650 E:654 ||| DT
use  ||| S:654 E:658 ||| NN
of  ||| S:658 E:661 ||| IN
NHP  ||| S:661 E:665 ||| NNP
models  ||| S:665 E:672 ||| NNS
is  ||| S:672 E:675 ||| VBZ
highlighted ||| S:675 E:686 ||| VBN
.  ||| S:686 E:688 ||| .
